Closed
The Marked Chart Wire · Health
Genmab
Genmab stock has doubled over the past three months following successful cancer drug trials. The results support the company's strategy to retain greater ownership of its developed medicines.
New to this? Read: Reading a stock chart
Abbott
Abbott's TECTONIC trial reported that its SonicForce coronary IVL system achieved a 97 percent procedural success rate and a 0.3 percent 30-day target lesion failure rate among 335 patients.
Johnson & Johnson
Johnson & Johnson says its Impella heart pumps are linked to lower mortality rates in patients. The company released the clinical data on Friday.
Fast headlines, summarized. Not verified and not advice. Check the full story before you act.